Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has reached an agreement to acquire Bioren, a California-based firm specializing in technology for optimizing antibodies, for an undisclosed amount.
Subscribe to our email newsletter
Antibody optimization technologies assist drug companies in developing medicines with improved properties such as greater and longer lasting efficacy. Bioren has developed technologies called Walk-Through Mutagenesis (WTM) and Look-Through Mutagenesis (LTM) to improve the drug development of antibodies.
“The acquisition of Bioren strengthens Pfizer’s commitment to the antibody space,” said Dr Nick Saccomano, Pfizer’s senior vice president for Worldwide Research Technology. “The ability to use and develop these technologies will help Pfizer identify new antibody leads as well as improve current antibodies in development.”
Over the last five years Pfizer has made significant internal and external investments, including the acquisition of Bioren, which have resulted in a substantial portfolio of therapeutic proteins and other macromolecules currently in various stages of development.